MedTrace Logo

Hand Sanitizer Use for Herpes Simplex Virus-1

NCT06135844 · Status: RECRUITING · Phase: EARLY_PHASE1 · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2023-11-18

No results posted yet for this study

Summary

The purpose of this pilot study is to determine if the use of Purell hand sanitizer alters the duration, level of pain and discomfort during treatment, and the size of the HSV-1 lesion. The duration of an HSV-1 (herpes) lesion is the primary endpoint for this study. Size, pain, and discomfort are the secondary endpoints.

Conditions

  • Virus
  • HSV-1
  • Herpes Simplex 1
  • Herpes Simplex Labialis

Interventions

DRUG

Purell Hand Sanitizer

Active ingredient. Ethyl alcohol 70%

DRUG

Medical Grade Mineral Oil

Inert ingredients: Saturated hydrocarbons, with a purity and chemical structure that differs substantially from food-grade or technical-/industrial-grade mineral oils.

Sponsors & Collaborators

  • Leciel Bono

    lead OTHER

Principal Investigators

  • Leciel Bono, MS · Idaho State University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
99 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2022-04-08
Primary Completion
2023-11-30
Completion
2023-11-30
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06135844 on ClinicalTrials.gov